481
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Can statins reduce mortality in critically ill COVID-19 patients? A retrospective cohort study

ORCID Icon, &
Pages 107-113 | Received 20 Nov 2022, Accepted 20 Jan 2023, Published online: 01 Feb 2023

References

  • Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038–3044.
  • Sharma A, Tiwari S, Deb MK, et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56(2):106054.
  • Asselah T, Durantel D, Pasmant E, et al. COVID-19: discovery, diagnostics and drug development. J Hepatol. 2021;74(1):168–184.
  • Fajgenbaum DC, Khor JS, Gorzewski A, et al. Treatments administered to the first 9152 reported cases of COVID-19: a systematic review. Infect Dis Ther. 2020;9(3):435–449.
  • Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020;14:1463–1465.
  • Castiglione V, Chiriacò M, Emdin M, et al. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):258–259.
  • Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep. 2002;4(1):34–41.
  • Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160–1164.
  • Koushki K, Shahbaz SK, Mashayekhi K, et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2021;60(2):175–199.
  • Rodrigues-Diez RR, Tejera-Muñoz A, Marquez-Exposito L, et al. Statins: could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020;177(21):4873–4886.
  • Reiner Ž, Hatamipour M, Banach M, et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490–496.
  • Kow CS, Hasan SS. The association between the use of statins and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2022;22(2):167–181.
  • Hariyanto TI, Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020;14(6):1613–1615.
  • Korani S, Bahrami S, Korani M, et al. Parenteral systems for statin delivery: a review. Lipids Health Dis. 2019;18(1):193.
  • Andrews L, Goldin L, Shen Y, et al. Discontinuation of atorvastatin use in hospital is associated with increased risk of mortality in COVID-19 patients. J Hosp Med. 2022;17(3):169–175.
  • Kuno T, So M, Iwagami M, et al. The association of statins use with survival of patients with COVID-19. J Cardiol. 2022;79(4):494–500.
  • Pineda A, Cubeddu LX. Statin rebound or withdrawal syndrome: does it exist? Curr Atheroscler Rep. 2011;13(1):23–30.
  • Daskalopoulou SS, Delaney JA, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J. 2008;29(17):2083–2091.
  • Ma B, Sun J, Diao S, et al. Effects of perioperative statins on patient outcomes after noncardiac surgery: a meta-analysis. Ann Med. 2018;50(5):402–409.
  • Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2014;130(24):e278–e333.
  • Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229–243.
  • Shen L, Qiu L, Wang L, et al. Statin use and in-hospital mortality in patients with COVID-19 and coronary heart disease. Sci Rep. 2021;11(1):23874.
  • Gupta A, Madhavan MV, Poterucha TJ, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):1325.
  • Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
  • Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020;95:304–307.
  • Ganjali S, Bianconi V, Penson PE, et al. Commentary: statins, COVID-19, and coronary artery disease: killing two birds with one stone. Metabolism. 2020;113:154375.
  • Sahebkar A, Serban C, Ursoniu S, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115(3):520–532.
  • Masoura C, Pitsavos C, Aznaouridis K, et al. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis. 2011;214(1):129–138.
  • Luscher TF, Creager MA, Beckman JA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation. 2003;108(13):1655–1661.
  • Tomizawa A, Hattori Y, Suzuki K, et al. Effects of statins on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: fluvastatin vs. rosuvastatin. Int J Cardiol. 2010;144(1):108–109.
  • Undas A, Brummel-Ziedins KE, Mann KG. Anticoagulant effects of statins and their clinical implications. Thromb Haemost. 2014;111(3):392–400.
  • Vuorio A, Watts GF, Kovanen PT. Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. J Intern Med. 2020;287(6):746–747.
  • Tsai PH, Lai WY, Lin YY, et al. Clinical manifestation and disease progression in COVID-19 infection. J Chin Med Assoc. 2021;84(1):3–8.
  • Oh TK, Song I-A, Jeon Y-T. Statin therapy and the risk of COVID-19: a cohort study of the national health insurance service in South Korea. J Pers Med. 2021;11(2):116.
  • Rey JR, Merino Llorens JL, Iniesta Manjavacas ÁM, et al. Influence of statin treatment in a cohort of patients admitted for COVID-19. Med Clin. 2022;158(12):586–595.
  • Cariou B, Goronflot T, Rimbert A, et al. Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: results from the CORONADO study. Diabetes Metab. 2021;47(2):101202.
  • Morse J, Gay W, Korwek KM, et al. Hyperglycaemia increases mortality risk in non-diabetic patients with COVID-19 even more than in diabetic patients. Endocrinol Diabetes Metab. 2021;4(4):e00291.
  • Mitacchione G, Schiavone M, Curnis A, et al. Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy. J Clin Lipidol. 2021;15(1):68–78.
  • Saeed O, Castagna F, Agalliu I, et al. Statin use and in-hospital mortality in patients with diabetes mellitus and COVID-19. J Am Heart Assoc. 2020;9(24):e018475.